Biomarker Market
Biomarker Market Forecasts to 2030 - Global Analysis By Product (Consumables, Software and Services), Type (Safety Biomarkers, Validation Biomarkers and Efficacy Biomarkers), Indication, Service, Application, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $58.12 BN |
|
Projected Year Value (2030) |
US $110.24 BN |
|
CAGR (2023 - 2030) |
14.2% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Biomarker Market is accounted for $58.12 billion in 2023 and is expected to reach $110.24 billion by 2030 growing at a CAGR of 14.2% during the forecast period. A biomarker, short for biological marker, refers to a measurable and quantifiable biological parameter or characteristic that serves as an indicator of a physiological or pathological process, a disease state, or a response to treatment. Biomarkers can be found in various biological samples, such as blood, urine, tissue, or other bodily fluids. Biomarkers can encompass a wide range of attributes, including genetic mutations, gene expression patterns, protein levels, enzyme activity, metabolite concentrations, and imaging features.
According to data published by ministry of health in China, about 203 million people are suffering from cardiovascular diseases and this number is expected to increase by 73% in 2030.
Market Dynamics:
Driver:
Increase in cancer incidence
Cancer is a complicated illness caused by a multi-stage carcinogenesis process with several molecular pathway events that make diagnosis, prognosis, and treatment difficult. A single marker is ineffective because cancer is complicated. Additionally, each kind of cancer has a unique molecular profile from the others. The identification of novel biomarkers opens up new avenues for the development of treatment approaches intended to correct dysregulation in cancer. As a result, the worldwide market will expand due to the development of biomarker research and the rising incidence of cancer.
Restraint:
Strict regulations
Strict rules and regulations are imposed to help build confidence and trust among healthcare providers, patients, and stakeholders in the biomarker market. This is crucial for the widespread adoption of biomarker-based diagnostics and therapies. Regulations promote standardization in the development, validation, and application of biomarkers. These regulations are complex and therefore become critical for making uninformed medical decisions. Thereby, this element hampers the market growth.
Opportunity:
Rising popularity of personalized medicine
Personalized medicine relies on biomarkers to identify specific genetic, molecular, or biochemical characteristics of a patient's disease. These biomarkers help determine the most effective treatment options, minimizing the need for trial-and-error approaches. By tailoring treatments to the individual patient's biological makeup, personalized medicine aims to increase treatment efficacy. Personalized medicine, guided by biomarkers, allows for the customization of drug dosage and treatment regimens based on individual patient characteristics, optimizing therapeutic outcomes. Its greater patient engagement and satisfaction followed up by early disease detection and prevention fuels the market growth.
Threat:
High development costs
The development of biomarkers requires significant financial investment and a multidisciplinary approach involving scientists, clinicians, regulatory experts, and other professionals. The high development costs reflect the complexity and rigor required to bring reliable biomarkers to clinical practice. Also, biomarker development often involves long and iterative processes; this prolonged timeline can result in cumulative costs. In addition, maintaining high standards of quality, recruiting skilled scientists and setting up technological infrastructure adds extra expenses which hinder the market demand.
Covid-19 Impact
The COVID-19 pandemic has a moderately beneficial effect on the biomarkers industry since biomarkers are essential for the creation of COVID-19 patient therapeutics. Biomarkers were discovered to be essential in the diagnosis and therapy in a number of studies. In addition, several organisations have introduced biomarker products to identify and treat COVID-19. These developments caused the market to expand throughout the pandemic era.
The cancer segment is expected to be the largest during the forecast period
The cancer segment is estimated to have a lucrative growth. Biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They are measurable biological indicators that can provide information about the presence or progression of cancer, as well as the likely response to specific treatments. It can help identify specific molecular or genetic characteristics of a tumor, allowing for the selection of targeted therapies that are more likely to be effective. From early detection to treatment selection, monitoring and research, biomarker contributes to more personalized and effective approaches to cancer diagnosis and treatment.
The diagnostics & research laboratories segment is expected to have the highest CAGR during the forecast period
The diagnostics & research laboratories segment is anticipated to witness the highest CAGR growth during the forecast period. Diagnostic labs play a vital role in monitoring disease progression and evaluating the effectiveness of treatments. Diagnostics and research laboratories play a pivotal role in advancing the field of biomarkers. They are involved in every stage of the biomarker development and application process, from discovery and validation to clinical testing, assay development, and patient care. Their work contributes significantly to improving disease diagnosis, treatment selection, and patient outcomes.
Region with largest share:
North America is projected to hold the largest market share during the forecast period owing to the high disease burden, rising consumer awareness of biomarkers, encouraging government efforts, technical breakthroughs, and improvements in healthcare infrastructure. In North America, the United States holds the largest market share. A significant element anticipated to fuel the region's growth is the presence of prominent firms in this area and the many organic and inorganic projects they have undertaken.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to its high prevalence of cancer, rising research initiatives, and low cost of clinical trials. Application of biomarkers in the drug discovery and development process is boosting key market players to invest in the research to develop novel biomarkers. In addition, an increase in funding for biotech and pharma companies, a rise in the number of CROs, and an increasing application scope of biomarkers are expected to facilitate regional market growth during the projected period.
Key players in the market
Some of the key players profiled in the Biomarker Market include GE Healthcare, Aushon Biosystem, Eisai Co. Limited, Abbott Laboratories, Inc., Epistem Limited, Agilent Technologies Inc., Roche Diagnostics Limited, Siemens AG, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson Services, Inc., Epigenomics AG, QIAGEN, Enzo Biochem Inc, Charles River Laboratories International Inc., Eurofins Scientific, LifeSign LLC, Bruker, Sino Biological Inc and Quest Diagnostics Incorporated.
Key Developments:
In November 2022, Siemens is expanding its generator circuit-breaker portfolio with a new compact version - the HB1-Compact (HB1-C). The versatile and highly customizable solution uses maintenance-free vacuum switching technology and addresses the most challenging of constraints.
In September 2022, GE Healthcare, a medical technology, diagnostics, and digital solutions company, launched its ‘Made in India’, ‘AI-powered’ Cath lab-Optima IGS 320 to advance cardiac care in India. It is built at Wipro GE Healthcare’s new Bengaluru factory and leverages the GE proprietary AutoRight technology.
Products Covered:
• Consumables
• Software
• Services
Types Covered:
• Safety Biomarkers
• Validation Biomarkers
• Efficacy Biomarkers
Indications Covered:
• Cancer
• Cardiovascular Disorders
• Infectious Diseases
• Neurological Disorders
• Immunological Disorders
• Other Indications
Services Covered:
• Assay Development
• Biomarker Validation & Testing
• Sample Preparation
• Other Services
Applications Covered:
• Drug Discovery & Development
• Disease Diagnostics
• DNA Fingerprinting
• Personalized Medicine
• Disease Risk Assessment
• Other Applications
End Users Covered:
• Pharmaceutical & Biotechnology Companies
• Hospitals & Specialty Clinics
• Diagnostics & Research Laboratories
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Biomarker Market, By Product
5.1 Introduction
5.2 Consumables
5.3 Software
5.4 Services
6 Global Biomarker Market, By Type
6.1 Introduction
6.2 Safety Biomarkers
6.3 Validation Biomarkers
6.4 Efficacy Biomarkers
6.4.1 Predictive Biomarkers
6.4.2 Surrogate Biomarkers
6.4.3 Pharmacodynamic Biomarkers
6.4.4 Prognostic Biomarkers
7 Global Biomarker Market, By Indication
7.1 Introduction
7.2 Cancer
7.3 Cardiovascular Disorders
7.4 Infectious Diseases
7.5 Neurological Disorders
7.6 Immunological Disorders
7.7 Other Indications
8 Global Biomarker Market, By Service
8.1 Introduction
8.2 Assay Development
8.3 Biomarker Validation & Testing
8.4 Sample Preparation
8.5 Other Services
9 Global Biomarker Market, By Application
9.1 Introduction
9.2 Drug Discovery & Development
9.3 Disease Diagnostics
9.3.1 Oncology
9.3.2 Neurology
9.3.3 Cardiology
9.4 DNA Fingerprinting
9.5 Personalized Medicine
9.6 Disease Risk Assessment
9.7 Other Applications
10 Global Biomarker Market, By End User
10.1 Introduction
10.2 Pharmaceutical & Biotechnology Companies
10.3 Hospitals & Specialty Clinics
10.4 Diagnostics & Research Laboratories
10.5 Other End Users
11 Global Biomarker Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 GE Healthcare
13.2 Aushon Biosystem
13.3 Eisai Co. Limited
13.4 Abbott Laboratories, Inc.
13.5 Epistem Limited
13.6 Agilent Technologies Inc.
13.7 Roche Diagnostics Limited
13.8 Siemens AG
13.9 Bio-Rad Laboratories
13.10 Thermo Fisher Scientific Inc.
13.11 Johnson & Johnson Services, Inc.
13.12 Epigenomics AG
13.13 QIAGEN
13.14 Enzo Biochem Inc
13.15 Charles River Laboratories International Inc.
13.16 Eurofins Scientific
13.17 LifeSign LLC
13.18 Bruker
13.19 Sino Biological Inc
13.20 Quest Diagnostics Incorporated
List of Tables
1 Global Biomarker Market Outlook, By Region (2021-2030) ($MN)
2 Global Biomarker Market Outlook, By Type (2021-2030) ($MN)
3 Global Biomarker Market Outlook, By Safety Biomarkers (2021-2030) ($MN)
4 Global Biomarker Market Outlook, By Validation Biomarkers (2021-2030) ($MN)
5 Global Biomarker Market Outlook, By Efficacy Biomarkers (2021-2030) ($MN)
6 Global Biomarker Market Outlook, By Predictive Biomarkers (2021-2030) ($MN)
7 Global Biomarker Market Outlook, By Surrogate Biomarkers (2021-2030) ($MN)
8 Global Biomarker Market Outlook, By Pharmacodynamic Biomarkers (2021-2030) ($MN)
9 Global Biomarker Market Outlook, By Prognostic Biomarkers (2021-2030) ($MN)
10 Global Biomarker Market Outlook, By Indication (2021-2030) ($MN)
11 Global Biomarker Market Outlook, By Cancer (2021-2030) ($MN)
12 Global Biomarker Market Outlook, By Cardiovascular Disorders (2021-2030) ($MN)
13 Global Biomarker Market Outlook, By Infectious Diseases (2021-2030) ($MN)
14 Global Biomarker Market Outlook, By Neurological Disorders (2021-2030) ($MN)
15 Global Biomarker Market Outlook, By Immunological Disorders (2021-2030) ($MN)
16 Global Biomarker Market Outlook, By Other Indications (2021-2030) ($MN)
17 Global Biomarker Market Outlook, By Service (2021-2030) ($MN)
18 Global Biomarker Market Outlook, By Assay Development (2021-2030) ($MN)
19 Global Biomarker Market Outlook, By Biomarker Validation & Testing (2021-2030) ($MN)
20 Global Biomarker Market Outlook, By Sample Preparation (2021-2030) ($MN)
21 Global Biomarker Market Outlook, By Other Services (2021-2030) ($MN)
22 Global Biomarker Market Outlook, By Application (2021-2030) ($MN)
23 Global Biomarker Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
24 Global Biomarker Market Outlook, By Disease Diagnostics (2021-2030) ($MN)
25 Global Biomarker Market Outlook, By Oncology (2021-2030) ($MN)
26 Global Biomarker Market Outlook, By Neurology (2021-2030) ($MN)
27 Global Biomarker Market Outlook, By Cardiology (2021-2030) ($MN)
28 Global Biomarker Market Outlook, By DNA Fingerprinting (2021-2030) ($MN)
29 Global Biomarker Market Outlook, By Personalized Medicine (2021-2030) ($MN)
30 Global Biomarker Market Outlook, By Disease Risk Assessment (2021-2030) ($MN)
31 Global Biomarker Market Outlook, By Other Applications (2021-2030) ($MN)
32 Global Biomarker Market Outlook, By End User (2021-2030) ($MN)
33 Global Biomarker Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
34 Global Biomarker Market Outlook, By Hospitals & Specialty Clinics (2021-2030) ($MN)
35 Global Biomarker Market Outlook, By Diagnostics & Research Laboratories (2021-2030) ($MN)
36 Global Biomarker Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
List of Figures
Figure 1 Global Biomarker Market Outlook (2021-2030) ($MN)
Figure 2 North America Biomarker Market Outlook (2021-2030) ($MN)
Figure 3 US Biomarker Market Outlook (2021-2030) ($MN)
Figure 4 Canada Biomarker Market Outlook (2021-2030) ($MN)
Figure 5 Mexico Biomarker Market Outlook (2021-2030) ($MN)
Figure 6 Europe Biomarker Market Outlook (2021-2030) ($MN)
Figure 7 Germany Biomarker Market Outlook (2021-2030) ($MN)
Figure 8 UK Biomarker Market Outlook (2021-2030) ($MN)
Figure 9 Italy Biomarker Market Outlook (2021-2030) ($MN)
Figure 10 France Biomarker Market Outlook (2021-2030) ($MN)
Figure 11 Spain Biomarker Market Outlook (2021-2030) ($MN)
Figure 12 Rest of Europe Biomarker Market Outlook (2021-2030) ($MN)
Figure 13 Asia Pacific Biomarker Market Outlook (2021-2030) ($MN)
Figure 14 Japan Biomarker Market Outlook (2021-2030) ($MN)
Figure 15 China Biomarker Market Outlook (2021-2030) ($MN)
Figure 16 India Biomarker Market Outlook (2021-2030) ($MN)
Figure 17 Australia Biomarker Market Outlook (2021-2030) ($MN)
Figure 18 New Zealand Biomarker Market Outlook (2021-2030) ($MN)
Figure 19 South Korea Biomarker Market Outlook (2021-2030) ($MN)
Figure 20 Rest of Asia Pacific Biomarker Market Outlook (2021-2030) ($MN)
Figure 21 South America Biomarker Market Outlook (2021-2030) ($MN)
Figure 22 Argentina Biomarker Market Outlook (2021-2030) ($MN)
Figure 23 Brazil Biomarker Market Outlook (2021-2030) ($MN)
Figure 24 Chile Biomarker Market Outlook (2021-2030) ($MN)
Figure 25 Rest of South America Biomarker Market Outlook (2021-2030) ($MN)
Figure 26 Middle East & Africa Biomarker Market Outlook (2021-2030) ($MN)
Figure 27 Saudi Arabia Biomarker Market Outlook (2021-2030) ($MN)
Figure 28 UAE Biomarker Market Outlook (2021-2030) ($MN)
Figure 29 Qatar Biomarker Market Outlook (2021-2030) ($MN)
Figure 30 South Africa Biomarker Market Outlook (2021-2030) ($MN)
Figure 31 Rest of Middle East & Africa Biomarker Market Outlook (2021-2030) ($MN)
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
